Long preclinical phase of AD pathology

Long Preclinical Phase Of Ad Pathology enters the Adult Cognitive Disease corpus through the work of Todd Golde (submission 131), and is indexed here as one of the concepts that submission puts to work.

The argument it belongs to

Todd Golde's submission is summarised in this corpus as:

AD is a complex, age-related disease where Abeta aggregation is the initiating causal event, but the linear amyloid cascade hypothesis is too simplistic. Genetic evidence from APP, PSEN1/2, and APOE conclusively supports Abeta as the trigger, while lifestyle factors, brain reserve, vascular health, and co-morbidities modulate the long prodromal phase and clinical trajectory.

Where it sits

The submission scores against the framework's convergence nodes as: ApoE4 hub 7 · neuroimmune interface 5 · endosomal nexus 3 · compensatory paradigm 3 · transcriptional / epigenetic 3 · cytoskeletal collapse 2.

Its declared subject matter: PERK-haplotype, DLX1, tau-toxicity-pathway, diversity-in-research, amyloid cascade hypothesis, genetics, APOE, brain reserve, preclinical AD, biomarkers, trisomy 21, lifestyle factors.

Named by the same submission

5 other concepts enter the corpus through the same paper, so they cover adjacent ground: Abeta aggregation as necessary initiating event · Genetic evidence as gold standard for causality · Multifactorial modulation of disease trajectory · PERK DLX1 Tau Axis · Translational Regulation in Tauopathy.

Assembled from the corpus rather than written: the summary is quoted from the submission that named it; the node scores are read from its dossier. It has not yet been expanded into an article.